Navigation Links
Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
Date:5/23/2011

LOS ANGELES, May 23, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC.BB:GNBP), a biotechnology company developing targeted cancer therapies, today announced that former California Governor, Gray Davis, has joined the company as Chairman of its Corporate Advisory Board. Governor Davis is committed to the improvement of healthcare and advancement of medical technologies.

During his tenure as governor, California became a leader in stem cell research as well as providing the highest levels of funding in the country for cancer and HIV research and treatment. Governor Davis set the most stringent standards for cancer clinical trials and made history by enrolling more children in the federal children's health insurance program (Healthy Families) than any state previously had.  He is currently Of Counsel at the Los Angeles office of law firm Loeb & Loeb.

"I believe personalized medicine is the future – and holds great promise for those suffering from chronic diseases," stated Governor Davis.

Genesis Biopharma Chairman and CEO, Anthony J. Cataldo, added, "Governor Davis brings tremendous value and insight as a person who has implemented his vision for a better healthcare system through advancements in technology and policy. He offers us his experience in organizational leadership, as well as his knowledge in working with regulatory bodies to help  bring our cancer therapies to market to save lives, reduce healthcare costs, and keep America at the forefront of innovative therapeutics."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Maryland Governor Martin OMalley to Visit Novavax in Celebration of HHS-BARDA Contract Award
2. Governor OMalley Announces State Grants Available For Maryland Bio Companies
3. Howard J. Leonhardt Announces Candidacy for Governor of California
4. GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California
5. Venture Capitalists to Invest in Promising PA Life Science Companies, Governor Rendell Says
6. The Biotechnology Industry Organization Honors Georgia Governor Sonny Perdue as Governor of the Year
7. Governor Rendell Says Life Science Industry Will Fuel New Breakthroughs, Generate Jobs for Decades to Come
8. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
9. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
10. Tengion Appoints A. Brian Davis Chief Financial Officer
11. Davis Phinney Foundation Launches Every Victory Counts Program to Inform and Empower People to Live Well With Parkinsons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):